Inhibition of aberrant crypt foci by chemopreventive agents

In Vivo

Volumn 12, Issue 2, 1998, Pages 159-166

  Olivo, Susan ^a   Wargovich, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Abberant crypt foci (ACF); Chemoprevention; Colon carcinogenesis

Indexed keywords

ALLYL SULFIDE; ANTIHISTAMINIC AGENT; ANTIOXIDANT; AZOXYMETHANE; CARCINOGEN; CAROTENOID; FARNESOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT GLYCOSIDE; PROTEIN P53; RETINOID; RUTOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER PREVENTION; COLON CARCINOGENESIS; CRYPT CELL; DRUG MECHANISM; GENETIC ANALYSIS; HISTOLOGY; NONHUMAN; ONCOGENE K RAS; PRECANCER; RAT; REVIEW; STEM CELL;

EID: 0031834931     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Chang WW: Histogenesis of colon cancer in experimental animals. Scandinavian Journal of Gastroenterology 19: 27-43, 1984.
2. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letters 37: 147-151, 1987.
3. McLellan EA, Medline A, Bird RP: Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 12: 2093-2098, 1991.
4. McLellan EA, Medline A, Bird RP: Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Research 51: 5270-5274, 1991.
5. Paulsen JE, Steffensen I, Namork E, Alexander J: Scanning electron microscopy of aberrant crypt foci in rat colon. Carcinogenesis 75: 2371-2373, 1994.
6. McLellan EA, Bird RP: Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Research 48: 6187-6192, 1988.
7. Caderni G, Giannini A, Lancioni L, Biggeri A, Dolara P: Characterisation of aberrant crypt foci In: carcinogen-treated rats: association with intestinal carcinogenesis. British Journal of Cancer 71: 763-769, 1995.
8. Wargovich MJ, Harris C, Chen C, Palmer C, Steele VE, Kelloff GJ: Growth kinetics and chemoprevention of aberrant crypts in the rat colon. Journal of Cellular Biochemistry Suppl: 51-54, 1992.
9. Zhang X, Stamp D, Minkin A, Corpet DE, Bruce WR, Archer MC: Promotion of aberrant crypt foci and cancer of the rat colon by thermolysed protein. Journal of the National Cancer Institute 84: 1026-1030, 1992.
10. Pretlow TP, O'Riordan MA, Somich GA, Amini SB: Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 13: 1509-1512, 1992.
11. Pretlow TP, Cheyer C, O'Riordan MA: Aberrant crypt foci and colon tumors in F344 rats have similar increases in proliferative activity. International Journal of Cancer 56: 599-602, 1994.
12. Moen CJA, van der Valk MA, Bird RP, Hart AAM, Demant P: Different genetic susceptibility to aberrant crypts and colon adenomas in mice. Cancer Research 56: 382-386, 1996.
13. Yamashita N, Minamoto T, Onda M, Esumi H: Increased cell proliferation of azoxymethane-induced aberrant crypt foci of rat colon. Japanese Journal of Cancer Research 85: 692-698, 1994.
14. Stopera SA, Davie JR, Bird RP: Colonic aberrant crypt foci are associated with increased expression of c-fos: the possible role of modified c-fos expression in preneoplastic lesions in colon cancer. Carcinogenesis 13: 573-578, 1992.
15. Stopera SA, Bird RP: Expression of ras oncogene mRNA and protein in aberrant crypt foci. Carcinogenesis 13: 1863-1868, 1992.
16. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, Ward MA, Stern HS, Gallinger S: K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 14: 1777-1781, 1993.
17. Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C, Alabaster O: Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 75: 775-778, 1994.
18. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221, 1989.
19. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
20. Stopera SA, Bird RP: Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci. Cytobios 73: 73-88, 1993.
21. Pretlow TP, O'Riordan MA, Kolman MF, Jurcisek JA: Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. American Journal of Pathology 136: 13-16, 1990.
22. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA: Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Research 51: 1564-1567, 1991.
23. Roncucci L, Medline A, Bruce WR: Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiology, Biomarkers Prevention 1: 57-60, 1991.
24. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR: Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Human Pathology 22: 287-294, 1991.
25. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA: Aberrant crypts in human. Suppl 16G: 55-62, 1992.
26. Roncucci L, Pedroni M, Fante R, Di Gregorio C, Ponz de Leon M: Cell kinetic evaluation of human colonic aberrant crypts. Cancer Research 55: 3726-3729, 1993.
27. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL: K-ras mutations in putative preneoplastic lesions in human colon. Journal of the National Cancer Institute 85: 2004-2007, 1993.
28. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H: Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 108: 434-440, 1995.
29. Losi L, Roncucci L, Di Gregorio C, Ponz de Leon M, Benhattar J: K-ras and p53 mutations in human colorectal aberrant crypt foci. Journal of Pathology 178: 259-263, 1996.
30. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S: Somatic APC and K ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Research 54: 5527-5530, 1994.
31. McLellan EA, Bird RP: Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Research 48: 6183-6186, 1988.
32. Okonogi H, Ushijima T, Shimizu H et al: Induction of aberrant crypt foci in C57BL/6N mice by 2-amino-9H-pyrido[2,3-b]indole (AaC) and 2-amino-3,8- dimethylimidazo[4, 5-f]quinoxaline (MeIQx). Cancer Letters 111: 105-109, 1997.
33. Takahashi M, Fukutake M, Yokota S, et al: Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. Journal of Cancer Research Clinical Oncology 122: 219-222, 1996.
34. Magnuson BA, Bird RP: Reduction of aberrant crypt foci induced in rat colon with azoxymethane or methylnitrosourea by feeding cholic acid. Cancer Letters 68: 15-23, 1993.
35. Shpitz B, Hay K, Medline A, et al: Aberrant crypt foci: early markers of malignancy in rat colon carcinogenesis. Proceedings of American Association for Cancer Research 34: A684, 1993.
36. Wargovich MJ, Chen CD, Jimenez A, et al: Aberrant crypts as a biomarker for colon cancer-evaluation of potential chemopreventive agents in the rat. Cancer Epidemiology, Biomarkers and Prevention 5: 355-360, 1996.
37. Wattenberg LW: Inhibitors of chemical carcinogenesis. Advances in Cancer Research 26: 197-226, 1978.
38. Wattenberg LW: Inhibition of carcinogenesis by minor dietary constituents. Cancer Research 52: 2085s-2091s, 1992.
39. Kensler TW: Chemoprevention by inducers of carcinogen detoxication enzymes. Environmental Health Perspectives 105 Suppl 4: 965-970, 1997.
40. Wargovich MJ, Chen CD, Harris C, et al: Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. International Journal of Cancer 60: 515-519, 1995.
41. Tudek B, Bird RP, Bruce WR: Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Research 49: 1236-1240, 1989.
42. Lam LK, Zhang J: Reduction of aberrant crypt formation in the colon of CF 1 mice by potential chemopreventive agents. Carcinogenesis 12: 2311-2315, 1991.
43. Steffensen IL, Paulsen JE, Eide TJ, et al: 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine increases the numbers of tumors, cystic crypts and aberrant crypt foci in multiple intestinal neoplasiamice. Carcinogenesis 18: 1049-1054, 1997.
44. Kristiansen E: The role of aberrant crypt foci induced by the two heterocyclic amines 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenyl- imidazo[4,5-b]pyridine (PhIP) in the development of colon cancer in mice. Cancer Letters 110: 187-192, 1996.
45. Zaidi NH, Pretlow TP, O'Riordan MA, et al Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16: 451-456, 1995.
46. Jacoby RF, Marshall DJ. Newton MA, et al: Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti- inflammatory drug piroxicam. Cancer Research 56: 710-714, 1996.
47. Shivapurkar N, Tang ZC, Alabaster O: The effect of high-risk and low-risk diets on aberrant crypt and colonic tumor formation in Fischer-344 rats. Carcinogenesis 13: 887-890, 1992.
48. Rao CV, Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14: 2219-2225, 1993.
49. Weisburger JH, Braley J, Reinhardt J et al: The role of fat and calcium in the production of foci of aberrant crypts in the colon of rats fed 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine. Environmental Health Perspectives 102 Suppl 6: 53-55, 1994.
50. Lasko CM, Bird RP: Modulation of aberrant crypt foci by dietary fat and caloric restriction; the effects of delayed intervention. Cancer Epidemiology, Biomarkers Prevention 4: 49-55, 1995.
51. Kristiansen E, Meyer O, Thorup I: Refined carbohydrate enhancement of aberrant crypt foci (ACF) in rat colon induced by the food-borne carcinogen 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ). Cancer Letters 105: 147-151, 1996.
52. Luceri C, Caderni G, Lancioni L, et al: Effects of repeated boluses of sucrose on proliferation and on AOM-induced aberrant crypt foci in rat colon. Nutrition Cancer 25: 187-196, 1996.
53. Narisawa T, Fukaura Y, Hasebe M, et al: Inhibitory effects of natural carotenoids, alpha-carotene, beta-carotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats. Cancer Letters 107: 137-142, 1996.
54. Onogi N, Okuno M, Komaki C, et al: Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats. Carcinogenesis 17: 1291-1296, 1996.
55. Alabaster O, Tang Z, Shivapurkar N: Inhibition by wheat bran cereals of the development of aberrant crypt foci and colon tumours. Food and Chemical Toxicology 35: 517-522, 1997.